Author

E. R. Woodruff

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1

Frequent Co-Authors

B. G. Bitler· 2 shared K. R. Jordan· 2 shared Z. L. Watson· 2 shared A. D. Jeong· 1 shared B. R. Corr· 1 shared C. A. Bailey· 1 shared C. Bailey· 1 shared E. Chuong· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

B. G. Bitler

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintApr 4, 2023

Combination CDC-like kinase inhibition (CLK)/Dual-specificity tyrosine-regulated kinase (DYRK) and taxane therapy in CTNNB1-mutated endometrial cancer

B. R. Corr, M. R. Moroney, E. R. Woodruff…·B. G. Bitler

This paper evaluates SM08502, a CLK/DYRK inhibitor, as a single-agent and in combination with paclitaxel for CTNNB1-mutated endometrial cancer, showing synergistic effects and tumor volume reduction in vitro and in vivo.

DOI 10.1101/2023.04.04.535570

humanexperimental assay

𝕏 PostBluesky

Cancer BiologybioRxivPreprintFeb 23, 2023

Combinatory EHMT and PARP inhibition induces an interferon response and a CD8 T cell-dependent tumor regression in PARP inhibitor-resistant models

L. L. Nguyen, Z. L. Watson, R. Ortega…·B. G. Bitler

DOI 10.1101/2023.02.23.529773

humanbulk RNA-seq

𝕏 PostBluesky